Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27875877 | 1.00 | SLC34A1 (0.90) | — | |
| Phosphoric Acid SCHEMBL28392064 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL31092547 | 1.00 | SLC34A1 (0.90) | — | |
| Phosphoric Acid SCHEMBL9276100 | 1.00 | SLC34A1 (0.90) | — | |
| Phosphoric Acid SCHEMBL138517 | 1.00 | — | — | |
| Phosphoric Acid SCHEMBL28704385 | 0.95 | SLC34A1 (0.82) | — | |
| Phosphoric Acid SCHEMBL27395577 | 0.95 | SLC34A1 (0.82) | — | |
| Phosphoric Acid SCHEMBL28193978 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL28065422 | 0.95 | — | — | |
| Phosphoric Acid SCHEMBL27770201 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118382646-A | Method for preparing composition containing hyaluronic acid crosslinked product | 株式会社 柳英制药 | 2024-07-23 | — | — | CN | claimed |
| US-20240173296-A1 | PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | claimed |
| CN-109554145-B | High-temperature-resistant peelable glue and preparation method thereof | 臻鼎科技股份有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-106893736-B | Method for improving secretion level of exogenous protein of bacillus licheniformis | 湖北大学 | 2020-07-07 | — | — | CN | claimed |
| US-9233898-B2 | Process for the preparation of 2-phenyl-1,3-propanediol | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-01-12 | — | — | US | claimed |
| US-20130231496-A1 | PROCESS FOR THE PREPARATION OF 2-PHENYL-1,3-PROPANEDIOL | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-09-05 | — | — | US | claimed |
| WO-2012032508-A1 | PROCESS FOR THE PREPARATION OF 2-PHENYL-1,3-PROPANEDIOL | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-03-15 | — | — | WO | claimed |
| CN-101458239-A | Highly effective liquid phase analyzing and measuring method for hypoglycemic agent-Voglibose and preparation thereof | BEIJING HOPE HUGE PHARM SCI CO (CN) | 2009-06-17 | — | — | CN | claimed |
| WO-2025230475-A1 | BETA-SILYL ALKYNOATES: VERSATILE REAGENTS FOR BIOCOMPATIBLE AND SELECTIVE AMIDE BOND FORMATION | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-11-06 | — | — | WO | disclosed |
| CN-119818450-A | Pharmaceutical composition of levoketorolac and preparation method thereof | 南京海融医药科技股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-118382646-A | Method for preparing composition containing hyaluronic acid crosslinked product | 株式会社 柳英制药 | 2024-07-23 | — | — | CN | disclosed |
| US-20240173296-A1 | PHARMACEUTICAL COMPOSITION OF (S)-KETOROLAC AND PREPARATION METHOD THEREFOR | NANJING HERON PHARMACEUTICAL SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| EP-4007615-B1 | A METHOD OF IN VITRO CHONDROCYTE AND CARTILAGE CULTURE TO OBTAIN MATERIAL FOR THE TREATMENT OF ARTICULAR CARTILAGE DEFECTS | ARTHEC SP Z O O (PL) | 2023-09-27 | — | — | EP | disclosed |
| US-11760972-B2 | Enhanced efficient nitrogen-fixing composite microbial system added with non-nitrogen-fixing bacteria and application thereof | Institute of Agricultural Resources and Regional Planning, CAAS (CN) | 2023-09-19 | — | — | US | disclosed |
| EP-2906242-A1 | DELIVERY OF SMALL INTERFERING RNA AND MICRO RNA THROUGH MEMBRANE-DISRUPTIVE, RESPONSIVE NANOSCALLE HYDROGELS | Board Of Regents, The University Of Texas System (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20150216814-A1 | DELIVERY OF SMALL INTERFERING RNA AND MICRO RNA THROUGH MEMBRANE-DISRUPTIVE, RESPONSIVE NANOSCALLE HYDROGELS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-08-06 | — | — | US | disclosed |
| US-8957102-B2 | Heterocyclic compound as protein kinase inhibitor | NEOPHARM CO., LTD. (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20120289509-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2012-11-15 | — | — | US | disclosed |
| WO-2011145100-A1 | PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY | HETERO RESEARCH FOUNDATION (IN) | 2011-11-24 | — | — | WO | disclosed |
| US-20110183983-A1 | HETEROCYCLIC COMPOUND AS PROTEIN KINASE INHIBITOR | NEOPHARM CO., LTD. (KR) | 2011-07-28 | — | — | US | disclosed |